AURINIA PHARMACEUTICALS INC (AUPH)
CA05156V1022 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 63.91M | 48.76M | 94.20M | 231.90M | 272.40M | |||
| Marketable Securities | 255.45M | 301.61M | 295.20M | 234.20M | 126.00M | |||
| Receivables | 28.91M | 24.09M | 13.50M | 15.40M | 1.00M | |||
| Inventories | 39.76M | 39.70M | 24.80M | 19.30M | 13.90M | |||
| Other Current Assets | 10.19M | 10.64M | 14.90M | 12.50M | 6.20M | |||
| Total Current Assets | 398.22M | 424.80M | 442.50M | 513.30M | 419.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 111.95M | 116.57M | 8.60M | 9.80M | 10.30M | |||
| Investments And Advances | 199.00K | 201.00K | N/A | 0.00 | 24.40M | |||
| Intangibles | 4.76M | 4.98M | 6.40M | 8.40M | 9.30M | |||
| Other Non-Current Assets | 1.50M | 1.52M | 13.30M | 11.80M | 200.00K | |||
| Total Non-Current Assets | 118.41M | 123.26M | 28.40M | 30.10M | 44.30M | |||
| TOTAL ASSETS | 516.63M | 548.06M | 470.90M | 543.40M | 463.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 13.72M | 14.61M | N/A | N/A | N/A | |||
| Accrued Expenses | 44.19M | 50.38M | 28.60M | 32.10M | 23.00M | |||
| Accounts Payable | 5.67M | 4.33M | 11.70M | 3.90M | 2.60M | |||
| Other Current Liabilities | 7.47M | 7.87M | 5.80M | 4.60M | 6.40M | |||
| Total Current Liabilities | 71.05M | 77.19M | 46.10M | 40.60M | 32.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 67.47M | 75.48M | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 18.63M | 17.44M | 19.30M | 23.60M | 23.90M | |||
| Total Non-Current Liabilities | 86.11M | 92.92M | 19.30M | 23.70M | 23.90M | |||
| TOTAL LIABILITIES | 157.16M | 170.11M | 65.40M | 64.30M | 55.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -953.07M | -942.32M | -864.30M | -756.10M | -575.20M | |||
| Additional Paid In Capital | 105.42M | 120.79M | 85.50M | 59.00M | 39.40M | |||
| Common Shares | 1.21B | 1.20B | 1.19B | 1.18B | 944.30M | |||
| Other Shareholders' Equity | -854.00K | -730.00K | -1.10M | -900.00K | -800.00K | |||
| Shares Outstanding | 143.69M | 143.83M | 142.30M | 141.60M | 126.70M | |||
| Tangible Book Value per Share | 2.47 | 2.59 | 2.80 | 3.32 | 3.15 | |||
| Total Shareholders' Equity | 359.48M | 377.95M | 405.40M | 479.10M | 407.80M | |||
| TOTAL LIABILITIES AND EQUITY | 516.63M | 548.06M | 470.90M | 543.40M | 463.70M | |||
| Statistics | ||||||||
| Debt/Equity | 0.19 | 0.20 | N/A | N/A | N/A | |||
| Current Ratio | 5.60 | 5.50 | 9.60 | 12.64 | 13.11 | |||
| Return On Assets (ROA) | -12.11% | -14.24% | -22.98% | -33.31% | -22.15% | |||
| Return On Equity (ROE) | -17.40% | -20.64% | -26.69% | -37.78% | -25.18% | |||
All data in USD